[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,251,300
  • Shares Outstanding, K 82,258
  • Annual Sales, $ 39,210 K
  • Annual Income, $ -311,350 K
  • EBIT $ -359 M
  • EBITDA $ -360 M
  • 60-Month Beta 1.95
  • Price/Sales 216.92
  • Price/Cash Flow N/A
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 64.82% (+0.23%)
  • Historical Volatility 66.08%
  • IV Percentile 55%
  • IV Rank 16.90%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 17) 3.06 (2.93%)
  • Put/Call Vol Ratio 1.42
  • Today's Volume 29
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 9,968
  • Open Int (30-Day) 9,868
  • Expected Range 101.54 to 107.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.64
  • Number of Estimates 10
  • High Estimate $-0.38
  • Low Estimate $-1.04
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +32.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.52 +4.50%
on 08/03/26
120.90 -13.98%
on 07/07/26
-9.51 (-8.38%)
since 07/02/26
3-Month
69.48 +49.68%
on 06/03/26
130.05 -20.03%
on 06/25/26
+20.41 (+24.42%)
since 05/04/26
52-Week
36.65 +183.77%
on 08/11/25
130.05 -20.03%
on 06/25/26
+60.34 (+138.20%)
since 08/04/25

Most Recent Stories

More News
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his...

KYMR : 104.40 (+4.08%)
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

NEW YORK , July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR)...

KYMR : 104.40 (+4.08%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK , July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies  KT-621...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...

KYMR : 104.40 (+4.08%)
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass.,...

KYMR : 104.40 (+4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 105.85
2nd Resistance Point 104.42
1st Resistance Point 102.37
Last Price 104.40
1st Support Level 98.89
2nd Support Level 97.46
3rd Support Level 95.41

See More

52-Week High 130.05
Last Price 104.40
Fibonacci 61.8% 94.37
Fibonacci 50% 83.35
Fibonacci 38.2% 72.33
52-Week Low 36.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.